Michael Karsy1, Jian Guan1, Adam L Cohen2,3, Randy L Jensen1,2, Howard Colman4,5,6. 1. Department of Neurosurgery, Clinical Neurosciences Center, University of Utah, Salt Lake City, UT, USA. 2. Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. 3. Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA. 4. Department of Neurosurgery, Clinical Neurosciences Center, University of Utah, Salt Lake City, UT, USA. howard.colman@hci.utah.edu. 5. Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. howard.colman@hci.utah.edu. 6. Department of Neurosurgery, The University of Utah, 175 North Medical Dr. East, Salt Lake City, UT, 84132, USA. howard.colman@hci.utah.edu.
Abstract
PURPOSE OF REVIEW: This review will discuss the role of several key players in glioma classification and biology, namely isocitrate dehydrogenase 1 and 2 (IDH1/2), alpha thalassemia/mental retardation syndrome X-linked (ATRX), B-Raf (BRAF), telomerase reverse transcriptase (TERT), and H3K27M. RECENT FINDINGS: IDH1/2 mutation delineates oligoden-droglioma, astrocytoma, and secondary glioblastoma (GBM) from primary GBM and lower-grade gliomas with biology similar to GBM. Additional mutations including TERT, 1p/19q, and ATRX further guide glioma classification and diagnosis, as well as pointing directions toward individualized treatments for these distinct molecular subtypes. ATRX and TERT mutations suggest the importance of telomere maintenance in gliomagenesis. BRAF alterations are key in certain low-grade gliomas and pediatric gliomas but rarely in high-grade gliomas in adults. Histone mutations (e.g., H3K27M) and their effect on chromatin modulation are novel mechanisms of cancer generation and uniquely seen in midline gliomas in children and young adults. Over the past decade, a remarkable accumulation of knowledge from the genomic study of gliomas has led to reclassification of tumors, new understanding of oncogenic mechanisms, and novel treatment strategies.
PURPOSE OF REVIEW: This review will discuss the role of several key players in glioma classification and biology, namely isocitrate dehydrogenase 1 and 2 (IDH1/2), alpha thalassemia/mental retardation syndrome X-linked (ATRX), B-Raf (BRAF), telomerase reverse transcriptase (TERT), and H3K27M. RECENT FINDINGS:IDH1/2 mutation delineates oligoden-droglioma, astrocytoma, and secondary glioblastoma (GBM) from primary GBM and lower-grade gliomas with biology similar to GBM. Additional mutations including TERT, 1p/19q, and ATRX further guide glioma classification and diagnosis, as well as pointing directions toward individualized treatments for these distinct molecular subtypes. ATRX and TERT mutations suggest the importance of telomere maintenance in gliomagenesis. BRAF alterations are key in certain low-grade gliomas and pediatric gliomas but rarely in high-grade gliomas in adults. Histone mutations (e.g., H3K27M) and their effect on chromatin modulation are novel mechanisms of cancer generation and uniquely seen in midline gliomas in children and young adults. Over the past decade, a remarkable accumulation of knowledge from the genomic study of gliomas has led to reclassification of tumors, new understanding of oncogenic mechanisms, and novel treatment strategies.
Authors: Andrew S Chi; Tracy T Batchelor; Daniel Yang; Dora Dias-Santagata; Darrell R Borger; Leif W Ellisen; A John Iafrate; David N Louis Journal: J Clin Oncol Date: 2013-04-01 Impact factor: 44.544
Authors: David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison Journal: Acta Neuropathol Date: 2016-05-09 Impact factor: 17.088
Authors: Angela J Sievert; Shih-Shan Lang; Katie L Boucher; Peter J Madsen; Erin Slaunwhite; Namrata Choudhari; Meghan Kellet; Phillip B Storm; Adam C Resnick Journal: Proc Natl Acad Sci U S A Date: 2013-03-26 Impact factor: 11.205
Authors: Dan Rohle; Janeta Popovici-Muller; Nicolaos Palaskas; Sevin Turcan; Christian Grommes; Carl Campos; Jennifer Tsoi; Owen Clark; Barbara Oldrini; Evangelia Komisopoulou; Kaiko Kunii; Alicia Pedraza; Stefanie Schalm; Lee Silverman; Alexandra Miller; Fang Wang; Hua Yang; Yue Chen; Andrew Kernytsky; Marc K Rosenblum; Wei Liu; Scott A Biller; Shinsan M Su; Cameron W Brennan; Timothy A Chan; Thomas G Graeber; Katharine E Yen; Ingo K Mellinghoff Journal: Science Date: 2013-04-04 Impact factor: 47.728
Authors: M Labussière; A L Di Stefano; V Gleize; B Boisselier; M Giry; S Mangesius; A Bruno; R Paterra; Y Marie; A Rahimian; G Finocchiaro; R S Houlston; K Hoang-Xuan; A Idbaih; J-Y Delattre; K Mokhtari; M Sanson Journal: Br J Cancer Date: 2014-10-14 Impact factor: 7.640
Authors: Laurens Kruidenier; Chun-wa Chung; Zhongjun Cheng; John Liddle; KaHing Che; Gerard Joberty; Marcus Bantscheff; Chas Bountra; Angela Bridges; Hawa Diallo; Dirk Eberhard; Sue Hutchinson; Emma Jones; Roy Katso; Melanie Leveridge; Palwinder K Mander; Julie Mosley; Cesar Ramirez-Molina; Paul Rowland; Christopher J Schofield; Robert J Sheppard; Julia E Smith; Catherine Swales; Robert Tanner; Pamela Thomas; Anthony Tumber; Gerard Drewes; Udo Oppermann; Dinshaw J Patel; Kevin Lee; David M Wilson Journal: Nature Date: 2012-08-16 Impact factor: 49.962
Authors: Neha Kamran; Mahmoud S Alghamri; Felipe J Nunez; Diana Shah; Antonela S Asad; Marianela Candolfi; David Altshuler; Pedro R Lowenstein; Maria G Castro Journal: Immunotherapy Date: 2018-02-01 Impact factor: 4.196
Authors: A Zygogianni; M Protopapa; A Kougioumtzopoulou; F Simopoulou; S Nikoloudi; V Kouloulias Journal: Clin Transl Oncol Date: 2018-01-15 Impact factor: 3.405
Authors: Anvesh Jalasutram; John L Caniglia; Kiran K Velpula; Maheedhara R Guda; Sarah E Bach; Andrew J Tsung Journal: Am J Transl Res Date: 2022-01-15 Impact factor: 4.060
Authors: Guo Gord Zhu; Khedoudja Nafa; Narasimhan Agaram; Ahmet Zehir; Ryma Benayed; Justyna Sadowska; Laetitia Borsu; Ciara Kelly; William D Tap; Nicola Fabbri; Edward Athanasian; Patrick J Boland; John H Healey; Michael F Berger; Marc Ladanyi; Meera Hameed Journal: Clin Cancer Res Date: 2019-10-15 Impact factor: 13.801